Primary Cutaneous Follicle Center Lymphoma (PCFCL)
Definition
Primary Cutaneous Follicle Center Lymphoma (PCFCL) is a rare form of cutaneous lymphoma originating from follicle center B-cells—a specific type of lymphocyte found in lymphoid tissue. It is an indolent, slow-growing malignancy with a favorable prognosis (10-year survival rate >90%). • Early diagnosis • Personalized treatment approaches for each case • Therapeutic plan optimization based on disease severity and spread
Morphology
Lesions may appear as solitary or grouped plaques or tumors, typically located on the scalp, forehead, trunk, and—rarely—on the lower limbs. Trunk lesions are often surrounded by erythematous infiltrated plaques, which may precede the development of the tumor by months or even years.
Etiology
The exact cause of Primary Cutaneous Follicle Center Lymphoma (PCFCL) is not fully understood. However, it appears to be associated with heightened immune system activity and may result from genetic predisposition or acquired abnormalities in the genetic material of B-lymphocytes. Some cases have been linked to chronic inflammation or autoimmune diseases. Infections or prior treatments that impact immune responses have also been implicated.
Diagnosis & Treatment
Diagnosis is typically established through skin biopsy and histopathological evaluation. Treatment depends on the extent and severity of the lymphoma. Common therapeutic strategies include chemotherapy, radiotherapy, and, in some cases, biological agents such as rituximab. Surgical excision is considered when the lesion is localized. While the prognosis is generally excellent in early-stage disease, the risk of recurrence increases in more advanced cases.
